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Abstract
Gliomas are a highly heterogeneous group of brain tumours that are refractory to treatment,
highly invasive and pro-angiogenic. Glioblastoma patients have an average survival time of
less than 15 months. Understanding the molecular basis of different grades of glioma, from
well differentiated, low-grade tumours to high-grade tumours, is a key step in defining new
therapeutic targets. Here we use a data-driven approach to learn the structure of gene regu-
latory networks from observational data and use the resulting models to formulate hypothe-
sis on the molecular determinants of glioma stage. Remarkably, integration of available
knowledge with functional genomics datasets representing clinical and pre-clinical studies
reveals important properties within the regulatory circuits controlling low and high-grade gli-
oma. Our analyses first show that low and high-grade gliomas are characterised by a switch
in activity of two subsets of Rho GTPases. The first one is involved in maintaining normal
glial cell function, while the second is linked to the establishment of multiple hallmarks of
cancer. Next, the development and application of a novel data integration methodology
reveals novel functions of RND3 in controlling glioma cell migration, invasion, proliferation,
angiogenesis and clinical outcome.
Author Summary
Gliomas are aggressive brain tumours that are invasive, heterogeneous, refractory to treat-
ment and show poor survival rates. Surgical resection and chemotherapy can increase
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a11111
OPEN ACCESS
Citation: Clarke K, Daubon T, Turan N, Soulet F,
Mohd Zahari M, Ryan KR, et al. (2015) Inference of
Low and High-Grade Glioma Gene Regulatory
Networks Delineates the Role of Rnd3 in Establishing
Multiple Hallmarks of Cancer. PLoS Genet 11(7):
e1005325. doi:10.1371/journal.pgen.1005325
Editor:W.K. Alfred Yung, University of Texas MD
Anderson Cancer Center, UNITED STATES
Received: December 16, 2014
Accepted: May 29, 2015
Published: July 1, 2015
Copyright: © 2015 Clarke et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The following datasets
are deposited within Gene Expression Omnibus:
Implantation of U87 cells on the chicken CAM:
GSE43674, RND3 silencing in U87 cells: GSE43812.
Funding: This study was supported by Cancer
Research UK (CRUK) grant C8504/A9488 and
BBSRC grant BB/I004556/1 LYNCONETawarded to
FF and partially supported by a grant from the
PlanCancer, Systems Biology 2012 program to AB.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
patient survival but ultimately the disease is fatal. Multiple grades of glioma exist, with
lower grades associated to better prognosis. While the majority of high-grade gliomas
occur de novo, it is common that low-grade gliomas progress to the more aggressive form
known as glioblastoma. In this article, we have shown that by combining advanced net-
work biology approaches with the right experimental models, we are able to reveal novel
regulatory circuits controlling multiple hallmarks of glioma. Through analysis of multiple
network models representing protein-protein interaction or gene co-expression data we
have revealed a switch in the role of regulatory Rho GTPases between low and high-grade
gliomas. Amongst these, we show that RND3 is up-regulated in glioblastomas and is a key
regulator of tumour proliferation, migration and invasion. We confirm that expression
and genomic copy number of RND3 are predictive of clinical outcome, suggesting that
changes in the activity of this particular Rho GTPase could be an early event associated to
transformation and tumour expansion.
Introduction
Gliomas are brain tumours originating from the glial cells and neural stem cells that surround
and support neurons [1]. They are classified on the basis of their clinical and histopathological
characteristics in four grades with progressively more severe features. Grade I and II gliomas
(astrocytomas, oligodendrogliomas and oligoastrocytomas) are considered relatively benign,
well-differentiated tumours and have 5 year survival rates of 59.9% [2]. Amongst patients diag-
nosed with low-grade gliomas, approximately 70% progress to grade IV glioblastoma multi-
forme (GBM) within 5–10 years of diagnosis [3]. De novo GBM constitute the majority of
grade IV glioma and are powerful inducers of angiogenesis, highly proliferative and invasive.
They are largely resistant to treatment and have poor prognosis with two years survival rates as
low as 3.3% [4].
A number of studies have identified key genomic alterations in GBM able to induce trans-
formation in non-tumorigenic cells such as mutations within EGFR [5] [6] and PDGFRA [7].
A molecular classification for GBM has been proposed subdividing the tumours based on their
molecular profile into 4 groups. This includes the classical type (EGFR amplification,
CDKN2A deletion), proneural type (PDGFRA amplification, PTEN deletion), the mesenchy-
mal (NF1 deletion) and the neural type [8]. However, angiogenic and invasive phenotypes are
observed across the different groups, making this classification unsatisfactory. For example,
EGFR amplification reminiscent of the classical type has been shown to drive invasive growth
[9]. Amplification and overexpression of EGFR leads to activation of Ras GTPase and Akt sig-
nalling pathways controlling cell growth, differentiation and survival of tumour cells [10] [11].
The complexity of the factors involved in the biology of gliomas makes it difficult to develop
a comprehensive model underlying GBM progression. Here we address this important chal-
lenge by integrating functional genomics datasets representing existing knowledge, clinical
studies and in vivo and in vitro glioma models.
We first show that network modules derived from a comprehensive integration of protein
interaction databases and defined by a high density of genes differentially expressed between
low and high-grade gliomas are consistent with the hypothesis that Rho GTPases may be part
of a key regulatory mechanism controlling hallmarks of high-grade glioma. A key feature of
GBM is invasion of tumour cells into the surrounding brain tissue and members of the Rho
GTPase family known to control actin cytoskeleton dynamics and cell migration have been
implicated in the survival and invasion of tumour cells [12] [13], [14]. In addition, RhoA
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expression correlates to tumour grade in astrocytomas [15]. We reconstruct stage specific gene
co-expression networks and analyse the connectivity profile of Rho GTPases. This reveals that
regulatory Rho GTPases separates in two groups, one active in low and the other in high-grade
gliomas. The functional profile of the putative targets of these two sub-sets predicts the func-
tional differences observed between low and high-grade glioma.
Further characterisation of a high-grade glioma transcriptional network highlights a pivotal
role of the Rho GTPase RND3 (also known as RhoE, Entrez: 390) in controlling tumour prolif-
eration, migration and invasion. Ultimately, the clinical relevance of this regulatory network is
proving that copy number variation in the RND3 gene is predictive of clinical outcome.
Results
Overview of the analysis and validation strategy
Our study is based on a complex data analysis workflow which includes several complementary
reverse engineering techniques to address the important challenge of generating and validating
hypotheses outlining the main factors underlying the control and maintenance of glioma stage.
The strategy we followed, which is summarised in Fig 1, is based on several cycles of data acqui-
sition, computational analysis, hypothesis generation and experimental validation.
The workflow consisted of five distinct but interconnected steps.
Step 1- Integration of protein-protein interaction networks with gene expression data
derived from a human clinical study: This represents low and high-grade gliomas and were
used to modularise a large network of known human protein-protein interactions (PPi). The
analysis of these modules identified a unique sub-network of regulatory factors, which repre-
sented a number of Rho GTPases.
Step 2- Revealing the linkage between subsets of Rho GTPases and glioma grade: Genome
scale gene expression data were used to construct co-expression networks centred on the regu-
latory Rho GTPases identified in step 1. This revealed a switch in activity of Rho GTPases
between grade II and grade IV glioma.
Step 3- Reverse engineering of regulatory networks from an in vivomodel:
We used the experimental glioma model in the chick chorioallantoic membrane [16] which
revealed regulation of Rho GTPases in the angiogenic and invasive phase of glioma develop-
ment. Network analysis revealed RND3 as the most connected factor for high-grade glioma.
Step 4- Validation step: The predictions from the network analysis were validated through
functional assays (apoptosis, proliferation, migration and angiogenesis in vitro and in vivo).
Step 5- Development of data integration strategy: We developed a novel, multi-level data
integration pipeline in order to shed light on the possible mechanisms of RND3 control of
tumour function. This revealed a link between RND3 and DNA replication factors such as
MCM3, which we validate in vitro.
Modularization of the human proteome identifies a cluster of GTPases
with potential regulatory activity in high-grade glioma
In order to gain insight in the mechanisms underlying the pathophysiology of human glioma,
we first developed an interaction network representing genes differentially expressed between
grade II astrocytoma and grade IV glioblastoma. We then applied a modularization procedure
to identify sub-networks of highly interconnected proteins, thus capturing important biological
networks potentially representative of the differences between low and high-grade glioma.
The procedure identified four main modules, with a highly statistically significant functional
enrichment profile (Fig 2). The entire list of significantly enriched Gene Ontology terms can be
Glioma Gene Regulatory Networks and the Role of RND3 in Cancer
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Fig 1. Overview of the analysis and validation strategy.
doi:10.1371/journal.pgen.1005325.g001
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found in S1 Dataset. Interestingly, the three largest modules (M2-4) mainly comprised genes up
regulated in grade IV gliomas and were enriched in typical effector functions in cancer. More
precisely, the largest of the effector modules (M2) was enriched in genes linked to apoptosis,
blood vessel development and inflammatory response and included the oncogenes JUN, FOS
and BCL3 (for reviews of known oncogenes see [17], [18]). The second largest module (M3)
included genes involved in cell adhesion, extracellular matrix, blood vessel development, adhe-
rens junctions and integrin complex and also included the oncogenes ERBB2, MET and EGF1.
Effector moduleM4 was predominantly enriched with proliferation related functions such as
cell cycle, DNA repair and DNA replication and the oncogenes MDM2, CDK6, FOXM1 and
BIRC5. We noticed that the smallest module (M1) comprised mainly proteins linked to GTPase
signalling (41/54), suggesting that this class of proteins may represent more important regula-
tors of tumour effector functions than previously anticipated. By examining the functional
enrichment profile of this cluster we discovered that the only enriched family of GTPases was
the Rho family with 5 members (CDC42, RHOJ, RAC2, RHOC, and RND3) (False Discovery
Rate< 1.93−6). This observation is consistent with the pro-tumour function of CDC42,
Fig 2. Protein-protein interaction networks representing glioma grade transition reveal functionally distinct modules. Proteins for which mRNA
abundance is higher (red nodes) or lower (green nodes) in grade IV glioma form highly interconnected modules (network modules M1-M4) defined by known
protein-protein interactions. Gene ontology analysis of each module (box M1-M4) reveal functional terms enriched within clusters (false discovery
rate < 10%). The number of genes mapped to each Gene Ontology term is shown in brackets and are coloured red if they are up or green if they are down-
regulated in grade IV glioma. Individually listed genes are known cancer oncogenes within each cluster, of which all were up-regulated in grade IV glioma.
doi:10.1371/journal.pgen.1005325.g002
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RHOG, RAC1 and RHOA in glioma [14] [13] [19] [20] [15] [21] [22]. However, our model
suggests a broader role of GTPases in glioma than previously thought. We therefore tested this
hypothesis by inferring the structure of grade II (Fig 3A) and grade IV (Fig 3B) glioma tran-
scriptional networks in the neighbourhood of all Rho GTPases.
Reverse engineering grade II and grade IV glioma transcriptional
networks identifies two functionally distinct subsets of GTPases of the
Rho family
We discovered that genes encoding for Rho GTPases were separated in two groups when char-
acterized by tumour grade-specific connectivity profiles (Fig 3D). Seven Rho GTPases (RND1,
RND3, RAC3, RHOA, RAC2, RAC1 and RHOC) showed a significantly greater connectivity in
grade IV glioma and seven (CHP, RHOD, RHOF, RHOB, RHOQ, RND2, RHOBTB3) showed
greater connectivity in grade II glioma. In order to validate this differential connectivity we
used expression data from grade II and grade IV glioma within the Cancer Genome Atlas data-
base. 16 Rho GTPases could be matched between the original data and TCGA grade II and
grade IV datasets, of which 13 (81%) showed the same trend as the original analysis (S2
Dataset).
Remarkably, Rho GTPases with a higher number of connections in grade IV tumours were
correlated to genes in the grade IV networks with a functional profile that included many of
the effector functions associated with high-grade glioma (immune response, regulation of apo-
ptosis, regulation of cell proliferation, response to cytokine stimulus, inflammatory response, cell
adhesion) (Fig 3C). On the other hand, in the grade II networks targets of Rho GTPases with a
higher proportion of connections in grade II glioma showed a functional profile consistent
with glial cells (putative target genes for this group of regulators were enriched with clathrin
coated vesicle membrane, dendrite, axonegensis, regulation of exocytosis, neuron development
and regulation of synaptic transmission functional terms) (Fig 3C). The full list of Gene Ontol-
ogy terms from the analysis of the grade II and grade IV networks can be found in S3 Dataset.
The functional profiles of the targets of the two groups of Rho GTPases also contained a subset
of similar functional terms such as synapse, cell projection, neurotransmitter transport, vesicle
membrane, cell junction. This suggests that in grade IV gliomas the link between Rho GTPases
and normal glial function is only partially interrupted.
Interestingly, we found that although most (15/19) of the Rho GTPases were differentially
expressed between grade II and grade IV gliomas, there was not a clear trend in the direction of
change (S2 Fig). Additionally, none of the Rho GTPases were differentially expressed between
grade II and grade III gliomas (S2 Fig). Overall, this supports the hypothesis that distinct sub-
sets of Rho GTPases are potentially important players in grade IV gliomas.
An in vivomodel of glioma development validates the predictions of the
inferred networks and identifies RND3 as a key regulatory molecule
In order to validate the networks developed from the clinical study, we implanted a grade IV
glioma derived cell line (U87MG) in the chicken egg chorioallantoic membrane (CAM) and
followed the transcriptional profile of tumour cells for the first 5 days post implantation with
10 equally spaced time points. In this well established in vivomodel, tumours implanted on the
CAM form avascular, solid tumours which stimulate angiogenesis and become vascularised
within 48 hours [16].
We found 2,999 unique genes differentially expressed during 5 days of tumour growth. We
used these genes to build a high level map representing the dynamics of transcriptional changes
in the developing tumour. A gene clustering procedure identified 14 distinct clusters which
Glioma Gene Regulatory Networks and the Role of RND3 in Cancer
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Fig 3. Transcriptional networks reveal two groups of Rho GTPases with divergent connectivity in grade II and grade IV glioma. A, B. Transcriptional
co-expression networks representing the neighbourhood of Rho GTPases in (A) grade II (5973 genes) and (B) grade IV (5621 genes) glioma. C.Gene
Glioma Gene Regulatory Networks and the Role of RND3 in Cancer
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were stratified according to their expression profiles (S3 Fig) (for gene lists of each cluster and
the Gene Ontology analysis see S4 Dataset). Functional profiling of the early transcriptional
response post-implantation (up to 12hrs) revealed an increase in expression of extracellular
matrix components. The intermediate transcriptional response (13 to 24hrs) was characterised
by a wave of transcriptional repression related to the inflammatory response, regulation of apo-
ptosis, lipid biosynthetic process and lysosomes functions. These included the extracellular
matrix remodelling genes, BMP2 and BMP6, chemokine signalling genes CCR1 and CCL20
and the inflammatory cytokine IL1A (S3 Fig). Consistent with the development of a fully vas-
cularized tumour at 48 hours post-implantation we saw a dramatic increase in the expression
of genes related to the cell cycle, cell adhesion, blood vessel development, and cell migration in
the time window between 37 and 48 hours.
Four Rho GTPases were up-regulated in this time window. Two of these (RHOC and
RND3) were among the Rho GTPases with a strong grade IV specific connectivity profile in
multiple datasets (Fig 3D) and the remaining two (RHOBTB1 and RHOBTB2) were non-
specific. Since GTPases and their potential transcriptional targets were all modulated at this
specific time window we hypothesized that if a cause and effect relationship exists it should be
within the time frame and resolution of our sampling (12 hours).
We therefore reverse engineered a static ARACNE mutual information network represent-
ing the neighbourhood of RND3, RHOC, RHOBTB1 and RHOBTB2 during the tumour
implantation time course (S4A Fig). Remarkably, we found that the resulting network shared
many properties with the grade IV network derived from the clinical study (Fig 3). First of all,
the GTPases which we predicted to be grade IV specific had a markedly larger number of con-
nections. Secondly, we discovered that RND3 was the most connected gene (S4B Fig) at a high
level of stringency (p< 10−8). Furthermore, we could verify a high degree of functional overlap
between genes connected to RND3 in the static CAM network and the grade IV network
inferred from the clinical samples (Fig 3E; S1 Table), making this gene an ideal candidate for
further analysis.
We then sought to experimentally define the transcriptional response linked to RND3 and
compare this with its predicted targets in the inferred grade IV networks. We therefore used
RNA interference to knock-down expression of RND3 by siRNA in U87 cells (siRND3) in
vitro and performed an expression profiling analysis. Differential expression analysis revealed
2,606 genes up-regulated and 2,099 genes down-regulated compared to non-silencing controls
(siControl/siRND3). A Gene Ontology analysis of these genes was consistent with the predic-
tions made from the reverse engineered networks (Fig 3E; S1 Table). The full Gene Ontology
analysis can be found in S5 Dataset. Functions related to tumour development including
inflammatory response, regulation of apoptosis, cell migration and cell cycle were differentially
regulated in directions consistent with the correlation patterns within primary glioma and U87
Ontology terms enriched within genes connected to grade II specific Rho GTPases or grade IV specific Rho GTPases (determined by connectivity, shown in
panel D). False discovery rate < 10%, number of genes indicated in brackets (grade II: green, grade IV: red). D. Two distinct subsets of Rho GTPases show a
significantly higher number of connections in either grade II (green) or grade IV (red) glioma. Differences in connectivity were expressed as the proportion of
grade II to grade IV connections. Rho GTPases with an absolute difference between tumour grades > 0.4 were considered grade specific. E. Transcriptional
profiling of U87 siRND3 cells induces a functional profile consistent with the network analysis in primary and CAM implanted tumours. Each Gene Ontology
term represents genes within that category which are linked to RND3 (connected to RND3 in the grade IV glioma network and/or connected to RND3 in the
CAM ARACNE network and/or differentially expressed in U87 siRND3 cells). These genes are either positively (red boxes) or negatively (green boxes)
correlated with expression of RND3 or up-regulated (red boxes) or down-regulated (green boxes) in U87 siRND3 cells. Gene Ontology terms matched to all 3
experiments are highlighted in blue. Genes in networks (A) and (B) are coloured according to whether they are connected to Rho GTPases with grade
specific connectivity in grade IV glioma (red nodes), grade II glioma (green nodes), or both grade II and grade IV (yellow nodes). Rho GTPases in networks
(A) and (B) are coloured according to the grade specific connectivity shown in panel D (red: grade IV, green: grade II, black: non-specific).
doi:10.1371/journal.pgen.1005325.g003
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implantation networks. Additionally, we noticed that RND3 knockdown resulted in the tran-
scriptional up-regulation of genes related to DNA repair, histone modification, RNA splicing
and transcription factor binding, and down-regulation of genes in cell communication, amino
acid phosphorylation, cell growth and response to oestrogen functional terms (S5 Fig). We also
noticed that the transcription of key genes involved in inflammation, proliferation, angiogene-
sis and extracellular matrix remodelling (including MMP2, HIF1A, IL1B, IL1A, IL1R1, MMP2,
VEGFA), processes vital to glioblastoma development, were down-regulated by RND3 knock-
down (S6 Fig).
RND3 is up-regulated in grade IV glioma
RND3 and other Rho GTPases are transcriptionally regulated in high-grade glioma (see S2
Fig). However, the expression of RND3 protein in different glioma grades is unknown. We
tested the expression of RND3 which on the basis of the numbers of inferred network connec-
tions we predicted to have differential activity across glioma grades. Remarkably, western blot
analysis of grade II, III and IV human glioma samples confirmed that protein expression corre-
lated with the transcriptional network connectivity. RND3 protein was significantly up-
regulated in grade IV gliomas compared to both grade II and grade III (Fig 4A and 4B). We
confirmed the difference in RND3 expression in tumour cells by immunohistochemistry analy-
sis of grade II, III and IV gliomas (Fig 4C). RND3 was found in the cytoplasm of tumor cells
but also in the nucleus.
We then set to characterise RND3 expression in relation to glioblastoma sub-types and
genetic mutations in key disease genes. We discovered that RND3 is up-regulated up to 2-fold
in GBM of the mesenchymal subtype with respect to the others (S13A Fig). Consistent with
this observation, other markers of mesenchymal subtype (MET, TLR4, RELB, TNF receptor
and CD44) were significantly down-regulated following RND3 knock down in glioblastoma
cells (S13B Fig).
We then tested whether individual genetic markers (copy number variations and SNPs)
may be able to explain the expression of RND3. Interestingly, we were able to explain up to 5%
of variance in RND expression with individual copy number variations and individual gene
expression measurements in the EGFR and CDKN2A genes. In addition, the expression of
NF1 was also able to explain a small part of RND3 expression (S13C Fig). We also used a ran-
dom forest regression approach to find combinations of genetic markers that could explain
RND3 expression. The resulting models were able to explain 14% (model with only genetic
mutations) and 21% (Model including both genetic mutations and gene expression) of the vari-
ance in RND3 expression (S13D and S13E Fig).
Experimental validation in vitro confirms the role of RND3 in controlling
glioma cell proliferation, apoptosis, cell migration and invasion
The observed transcriptional changes suggest alterations in cell proliferation, migration and
cell cycle. In order to test whether the transcriptional signature truly reflects physiological
changes we first used RNA interference and a panel of in vitro assays to test proliferation, inva-
sion, migration and cell cycle.
The results obtained were fully consistent with our predictions, suggesting that knock-down
of RND3 induced an anti-tumour phenotype in U87 cells, which express high levels of RND3
(S7A Fig). Proliferation, migration and invasion were all significantly reduced in U87
RND3-depleted cells (Fig 5A–5C). Bromodeoxyuridine (BrdU) labelling of RND3-depleted
cells revealed significantly reduced numbers of cycling cells (Fig 5D; siRND3 U87 18.8±0.55%
cells; control 32.3±0.32% cells).
Glioma Gene Regulatory Networks and the Role of RND3 in Cancer
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We then performed an over-expression experiment to test whether increased levels of
RND3 may have the expected effect on proliferation and migration. Firstly, the expression of
RND3 was determined in several cell lines from different glioma grades. As shown in patient
samples, a grade II cell line, 1321N1, expressed low levels of RND3 (S7A Fig). Two grade IV
cell lines were assessed, U87 and T98G cells. T98G cells expressed a much lower amount of
RND3 than U87 cells (S7A Fig). A lentiviral expression of myc-RND3 was then used to over-
express RND3 in both low-expressing cell (S7B Fig). Both cell line morphologies were changed
by myc-RND3 overexpression and this was validated by RND3-GFP over-expression (S7C
Fig 4. RND3 is up-regulated in grade IV glioma. A. RND3 expression determined by western blot in patient samples from different glioma grades as
determined after anatomopathological analysis. B. Densitometric analysis of RND3 protein from western blot shown in (A) presenting the ratio of RND3 to
tubulin. C. Immunohistochemical analysis of RND3 expression in grade II, III and grade IV patient tumors (bar 100 μm), magnified images are presented in
left panels. Data is representative of 4 or more tumours. *** p < 0.001, ** p < 0.01, * p < 0.05, values +/- SEM.
doi:10.1371/journal.pgen.1005325.g004
Glioma Gene Regulatory Networks and the Role of RND3 in Cancer
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Fig 5. In vitro and in vivo RND3 silencing reduces cell proliferation andmigration, induces apoptosis and reduces tumour mass. A, B. (A) Invasion
and (B) migration of U87 siRND3 and siControl cells determined by scratch wound assay. C. Proliferation of U87 siRND3 and siControl cells determined by
Glioma Gene Regulatory Networks and the Role of RND3 in Cancer
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Fig). F-actin staining showed formation of a large lamellipodia at the front of the cells and a
decrease of cell volume.
This overexpression impacted both cell lines in a manner fully consistent with the RNA
interference assays. Both proliferation and migration (Fig 5E–5H) were significantly increased
in both 1321N1 and T98G cells. These results confirmed the importance of RND3 in cell
aggressiveness behaviours.
We then validated the hypothesis that RND3 expression is linked to apoptosis. RND3-de-
pleted cells showed an increase in cell death evidenced by a dramatic increase in both con-
densed nuclei (Fig 5I) and cleavage of caspase 3 (Fig 5J). Use of the small molecule inhibitor Y-
27632 to inhibit ROCK activity did not significantly affect cell death in RND3-depleted cells
suggesting that the effects of depleting RND3 were not mediated via ROCK1, which interacts
with RND3 and is essential for its canonical function controlling cytoskeleton remodelling
[23].
RND3 knockdown blocks in vivo tumour expansion
Encouraged by the in vitro analysis we performed an in vivo implantation of U87 siRND3 cells
in the chicken egg CAM. Phenotypic characterization of the resulting tumours was again fully
consistent with the results of the in vitro analysis. Visual inspection showed that tumours
appeared dramatically reduced in size 48 hours after implantation (Fig 5K and 5L). This was
accompanied by a substantial reduction in proliferating cells shown by a 62% reduction in Ki-
67 expression (Fig 5M–5O). Further quantification of the tumour surface area in a horizontal
section confirmed an average 40% reduction in tumour expansion (Fig 5P; siRND3 U87
1.8x106 pixels ±1.7x105; control U87 2.9x106 pixels ±2.3x105). We also quantified tumour
thickness after immunostaining which demonstrated a reduction of 50% (Fig 5Q; siRND3 U87
188.8μm ± 23.2; control U87 382.3μm±37.3). Consistent with the reduced expression of
VEGFA mRNA in siRND3 transfected U87 cells, blood vessel density in siRND3 tumours was
significantly lower compared to control tumours (Fig 5R; siRND3 oligo B U87 10.6±2.79; con-
trol U87 23.8±2.13), suggesting a disrupted angiogenesis process. Additional histological analy-
sis of tumours revealed reduced Vimentin expression in line with the reduced tumour mass (S8
Fig). Pericyte coverage of blood vessels within the tumour, detectable by Desmin staining, was
increased in siRND3 tumours (S8 Fig). Taken together, this supports a critical role of RND3 in
tumour expansion by modulating angiogenesis, cell migration, invasion, apoptosis and cell
cycle dynamics.
A novel multi-level data integration algorithm identifies a potential
mechanism for RND3-dependent cell cycle control
Some of the pro-tumour effects of RND3 (migration and invasion) are likely to be a direct con-
sequence of its known role in cytoskeleton remodelling [24]. However, the mechanisms behind
confluence measurements. D. Percentage of cells showing BrdU incorporation into DNA in U87 siRND3 and siControl cells. E, F.Migration of RND3
overexpressing (E) 1321N1 and (F) T98G cells and Turbo-GFP control cells determined by scratch wound assay.G, H. Proliferation of RND3 overexpressing
(G) 132N1 and (H) T98 cells. I. The average number of condensed nuclei in U87 siRND3 and siControl cells treated with Y27632 and/or cisplatin prior to
imaging. J. Levels of cleaved Caspase 3 in U87 siRND3 and siControl cells with/without Y27632 and cisplatin treatment were determined by western blot.K,
L. Representative image of 5 day old tumours derived from (K) wild-type and (L) U87 siRND3 cells implanted on the chicken CAM.M, N. Representative
image of Ki-67 expression in 5 day old tumours derived from (M) wild-type and (N) U87 siRND3 cells. Magnification x10, scale bar 200μm, inset magnification
x40.O-R.Quantification of (O) Ki-67 expression, (P) tumour surface area, measured as tumour area in pixels, (Q) tumour thickness, (R) relative density of
blood vessels in 5 day old tumours.A-J.Data is representative of 3 independent experiments. K-R. Data is representative of 4 or more tumours.
*** p < 0.001, ** p < 0.01, * p < 0.05, values +/- SEM.
doi:10.1371/journal.pgen.1005325.g005
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control of cell proliferation and apoptosis are less easy to interpret, particularly considering
that these are ROCK1 independent (Fig 5I and 5J). Therefore, in order to further explore
RND3-dependent growth and survival, we designed an unbiased, open-ended approach based
on the de-novo identification of RND3 interacting proteins followed by computational
analysis.
Co-immunoprecipitation of RND3 flag tagged protein and subsequent mass spectrometry
analysis identified 205 putative interactors of RND3. Functional profiling of the interactors
revealed primarily nuclear associated proteins involved in regulation of translation, the nuclear
lumen, intracellular transport and cell division (Table 1).
In order to identify a specific mechanism that may explain RND3 tumour growth we devel-
oped a novel network modularization approach designed to identify a sub-network of the
human interactome enriched with proteins interacting with RND3 and at the same time highly
correlated in the CAM expression profiling time course.
The algorithm (see S1 Text for details of the development and validation of the algorithm)
identified a significant sub-network (p<10−16) containing 49 genes (Fig 6A). This network
included genes known to be involved in Rho-mediated cytoskeletal remodelling (ROCK1,
Vimentin, Moesin, Radixin) as well as components of NFKB signalling (IKBKAP, NFKBIA),
apoptosis (Caspase 3, PSME3) and, interestingly, 4 nuclear proteins involved in DNA licensing
(MCM3, MCM4, MCM5, MCM7) as well as the important cell cycle regulator CDC2. During
the cell cycle RND3 expression has been shown to increase during G1 followed by a rapid
decrease at S phase [25]. Taken together, this raised the hypothesis that RND3 may be associ-
ated to nuclear proteins and that this may be part of the mechanism regulating cell cycle. Con-
sistent with recent reports [26] [27] and the immunohistochemistry analysis (Fig 4C) we
demonstrated by confocal imaging of U87 cells that RND3 can localise to the nucleus (Fig 6B)
and that it is detectable by western blot in nuclear fractions (S11 Fig). Complementing evidence
of the nuclear occupancy of RND3, we performed Fluorescence recovery after photo-bleaching
(FRAP) experiments (S12 Fig), showing motile RND3-GFP is able to partially recover into
bleached regions in both the nuclear and cytoplasmic compartments. We hypothesised that
RND3 might be controlling the cellular localisation of the nuclear DNA licensing factors and
consistent with this we verified that MCM3 could be co-immunoprecipitated with RND3
(Fig 6C) in U87 cells. A previous report has suggested that high levels of MCM3 protein in the
nucleus may result in cell cycle arrest [28]. We observed that depletion of RND3 leads to
nuclear accumulation of MCM3 (Fig 6D–6F). Taken together, this suggests a novel role for
RND3 in controlling cell cycle by modulating the localisation of the DNA licencing protein
MCM3.
Table 1. Gene Ontology categories of 205 putative RND3 binding partners. Gene Ontology terms in
bold were significantly enriched (false discovery rate < 10%).
Category Term
GOCC Nuclear lumen (55)
GOMF Nucleotide binding (62)
GOMF ATPase activity (23)
GOBP Intracellular transport (22), protein transport (19)
GOBP Regulation of translation (9)
GOBP DNA repair (12)
GOCC Chromosome (18)
GOCC Mitochondrial envelope (13)
GOBP Cell division (10), Cell cycle (15)
doi:10.1371/journal.pgen.1005325.t001
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Fig 6. Reverse engineering networks from integrated datasets reveals a novel role of RND3 in cell cycle control. A. Protein-protein interaction
network representing a module of RND3 interactors that are co-expressed during tumour development in the CAM. B. Confocal microscopy of U87 cells
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Copy number variation (CNV) and expression of RND3 is predictive of
clinical outcome
Having shown that RND3 plays a role in the development of GBM, we asked whether its
expression could be influenced by genetic mutations such as copy number variation of the
RND3 locus, and if both expression and CNV may be predictive of patient survival.
We first approached this question using data available within the REMBRANT database of
functional genomics data [29]. We focused on GBM patients and found that patients with an
increased RND3 copy number showed significantly lower probability of survival compared to
patients with a normal or reduced RND3 copy number (Fig 7A). Using the same database we
then could verify that RND3 gene expression was also predictive of survival and that RND3
CNV and expression were positively correlated (Fig 7B).
Next, in order to validate this initial finding, we performed survival analysis using the Can-
cer Genome Atlas (TCGA) database of GBM expression and copy number. Consistent with the
survival analysis performed using REMBRANDT, both RND3 expression and CNV were pre-
dictive of survival (S9 Fig).
Taken together these finding suggest that genetic mutations can trigger increased expression
of RND3 and that this correlates with clinical outcome.
Discussion
The importance of our work is two-fold. Firstly, we demonstration that computational integra-
tion of multiple data sources is an effective strategy to unravel the structure of biological
expressing RND3-GFP with DAPI stain (red). Scale bar: 10μm. C. Immunoprecipitation using anti-Flag antibody in U87 cells transfected with RND3-Flag or
Flag. Western blot analyses used the indicated antibodies. D, E. Immunostaining of MCM3 in (D) U87 siControl cells and (E) U87 siRND3 cells. Scale bar:
10μm. F.Quantification of proportion of nuclear and cytoplasmic MCM3 detected by western blot in U87 siRND3 and siControl cells. Data is representative of
3 replicate experiments. *** p < 0.001, ** p < 0.01, * p < 0.05, values +/- SEM.
doi:10.1371/journal.pgen.1005325.g006
Fig 7. RND3 expression and copy number variation is a significant risk factor for glioma patients. A. The Kaplan-Meier survival curves for glioma
patients with amplification (red, n = 45) or deletion (green, n = 72) of the RND3 locus, determined from SNP frequency data within the REMBRANDT
database, log rank p value = 0.0301.B. The Kaplan-Meier survival curves for glioma patients with RND3 overexpression (red, n = 89) or comparable
expression (orange, n = 88) versus non-tumour samples, log rank p value = 0.0006. All analysis performed using the online REMBRANDT database tools.
doi:10.1371/journal.pgen.1005325.g007
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networks underlying the development of human glioma. Secondly, our models have
highlighted that low and high-grade gliomas are characterised by a switch in the activity of two
different sets of Rho GTPases, among which RND3 is a key regulator of tumour proliferation,
migration, apoptosis and invasion. Furthermore, RND3 CNV correlates to its expression and is
predictive of survival, suggesting that changes in the activity of this particular Rho GTPase
could be an early event associated to transformation and tumour progression.
The role of Rho GTPases in glioma
An important property that emerged from our inferred networks is the existence of two sets of
Rho GTPases, which may target functionally different molecular networks and explain the
more aggressive nature of high-grade Gliomas.
Overall, this hypothesis is consistent with the literature. Among the seven Rho GTPases that
are linked to grade II networks we could find little evidence in the literature for a mechanistic
linkage with tumour transformation or progression. On the contrary, we could find evidence of
their involvement in normal tissue functions such as migration of neuronal shape change dur-
ing brain development (RND2)[30], regulation of actin cytoskeleton involved in vesicle traf-
ficking (RHOD, RHOF) [31] [32], sub-cellular trafficking of growth factor receptors in normal
cells (RHOB) [33] [34], and protein degradation (RHOBTB3, CHP) [35] [36]. Among these,
only RHOB has been firmly linked to high-grade glioma albeit with contrasting results. Repres-
sion of RHOB has been shown to increase motility and invasion in glioblastoma cells [37].
However, it has recently been shown to support glioblastoma tumorigenesis [38].
On the other hand, 6/7 of the Rho GTPases linked to high-grade glioma in our model has
previously been shown to play a role in GBM. This includes effects on cell invasion (RAC1
[39], RAC2 [40], RAC3 [39], RHOA [41], RHOC [42]), focal adhesion formation (RHOA
[43]), stemness of glioma precursor cells (RAC1 [44]), cell proliferation (RAC1 [45], RND3
[46]) and cell cycle (RND3 [25]).
RND3, a pro-tumour gene in glioblastoma
Our work shows that down-regulation or overexpression of RND3 supports its role as a pro-
tumour gene in glioblastoma controlling proliferation, migration and invasion using different
glioma cell lines. Inactivation of RND3 also alters survival at both the level of cell cycle regula-
tion and induction of apoptosis. Importantly, its expression appears to be regulated by genetic
mutations such as CNV rather than as a secondary event down-stream of other cancer signal-
ling pathways. Our work identifying RND3 as a pro-tumour gene is consistent with data from
endometroid adenocarcinoma cells where RND3 is described as a p53 inducible pro-tumour
gene, promoting proliferation and survival of cells following DNA damage [47]. However, its
role in other types of cancer may be different. RND3 is under-expressed in prostate cancer and
induces apoptosis and cell cycle arrest [48].
In addition, a previous study in glioma positioned RND3 as an anti-tumour gene, decreas-
ing proliferation and inducing apoptosis in U87 cells [46]. However, these data were based on
the overexpression of RND3 in a cell type that already expresses high levels of RND3 (S7A
Fig), leading to a non-physiological situation. It is also possible that RND3 has a bell-shaped
activity profile, where inhibition is seen when it is absent or low and when it is highly overex-
pressed such as after transfection into cells.
The strength of our approach, in contrast to many of these previous studies, relies in the fact
that a systems biology approach that combines clinical and experimental datasets has been
used in our study. This provides us with an array of concording results that clearly point to a
pro-tumour role of RND3 in glioblastoma.
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Towards predictive modelling of glioma development
In this article, we have shown that by combining advanced network biology approaches with
the right experimental models, we are able to reveal novel regulatory circuits controlling multi-
ple hallmarks of cancer. However, these findings should stimulate several research directions.
Firstly, while we now better understand the role and clinical relevance of RND3 in human Gli-
oma, we still do not have a mechanistic model explaining the switch between networks of nor-
mal and abnormal regulatory Rho GTPases, which we hypothesise drives the establishment of
a progressively more severe cancer phenotype, presumably at the expenses of normal glial func-
tion. In this context, we have identified MCM3, a DNA licencing factor, as a new interacting
partner. This interaction may participate, in addition to its known modulatory activity on
RhoA activity, to the biological effects triggered by RND3 in glioma cells. The specific role of
the RND3-MCM3 interaction is at present not established. One may speculate that it is
involved in nuclear-cytoplasmic shuttling. Establishing a complete mechanistic model will
involve extensive experimental analysis of the role of each regulator and, eventually, the devel-
opment of a mathematical model to simulate glioma progression. Ultimately, the integration of
molecular, phenotypic and clinical endpoints within a computational model will provide a new
set of investigative and predictive tools to support clinical decision-making.
Methods
Ethics statement
Human tumour samples are provided by Rolf Bjerkvig (University Bergen, Norway). He has
ethical permission to store biopsy specimens from human patients in a biobank, as well as cor-
responding xenografts in animals. Regional ethical approval number: 013.09. The tissue col-
lected is anonymized at the department of Neurosurgery at Haukeland University Hospital.
Animal experiments: the animal experiments are conducted in the Animalerie Mutualisée, Bor-
deaux, France. The number of authorisation is B33-522-22 and was obtained February 28
2012. The approval for experimentation has been obtained from the University of Bordeaux
ethical committee (approval number R-45GRETA-F1-10).
Identification of genes differentially expressed in low and high-grade
glioma
Differentially expressed genes between grade II (n = 45) and grade IV (n = 81) gliomas were
identified using an existing microarray study by Sun et al [49]. Raw data were downloaded
from the GEO database (accession GSE4290) and normalized using the Robust Multiarray
Average algorithm (RMA) [50]. Statistical significance was determined using a t-test followed
by correction for multiple comparisons using the Benjamini-Hochberg method to estimate the
false discovery rate (FDR) [51]. Genes with a log2 fold change greater than 1.5 and an
FDR< 1% were selected. This transcriptional signature was compared to a transcriptional sig-
nature from a similar study comparing grade II (n = 50) and grade IV (n = 24) glioma (acces-
sion GSE52009) for validation purposes. Both transcriptional signatures showed a very high
level of similarity (FDR< 1%) when compared using Gene Set Enrichment Analysis [52]
(S1 Fig).
Modularization of the human protein interactome representing tumour
stage transition
In order to achieve this goal we first subset the human protein interactome by selecting pro-
teins encoded by genes differentially expressed between grade II and grade IV glioma samples.
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The interactions between this subset of proteins were identified using the Michigan Molecular
Interaction (MiMI) protein interactions databases [53], which merged and integrated a number
of protein interactions databases such as BioGRID [54] and HPRD [55]. This protein-protein
interaction (PPI) network consisted of 1423 nodes and 18,681 edges. Hubs were identified
within the network by calculating the percolation score [56] for each node, in order to identify
potentially important proteins. There were 93 hub nodes with a percolation score greater than
2 standard deviations above the mean. The complete glioma stage network was constructed by
selecting the first neighbours of these network hubs, resulting in 682 nodes and 2472 edges.
The network was modularized using the GLaY algorithm for community detection [57].
The chorioallantoic membrane (CAM) glioblastoma implantation model
U87 glioblastoma cells were maintained in DMEM, 10% FBS, antibiotics and L-glutamine. U87
cell pellets were deposited on the chicken egg CAM at developmental day 10 as previously
described [16]. For the transcriptomics time-course, tumours were dissected from the CAM
and snap frozen every 12 hours following implantation at developmental day 10 until develop-
mental day 15 (10 time points). To assess the effect of RND3 silencing on tumour growth on
the CAM, U87 cells were transfected with siRNA for RND3 or non-silencing control siRNA
before implantation. Tumours were imaged every day and grown for 5 days after deposition on
the CAM. The tumour was then dissected and mounted in OCT and processed for measure-
ment and immunohistochemistry.
Reverse engineering transcriptional networks in glioma
Low and high-grade glioma transcriptional networks were generated from grade II and grade
IV samples from the Sun et al dataset (GSE4290) [49] and Cancer Genome Atlas datasets
(TCGA) (http://cancergenome.nih.gov/). Normalised, batch corrected TCGA datasets were
downloaded from the MD Anderson MBatch (http://bioinformatics.mdanderson.org/
tcgambatch/) website. Mutual information networks were inferred using the ARACNE method
[58] with the Rho GTPases set as hub genes. Significant gene-gene interactions were defined
using a p-value cut-off of 1x10-5.
A dynamic model of gene expression in the developing tumour during the first 5 days fol-
lowing U87 deposition on the CAM has been inferred from our microarray data using a cus-
tom bioinformatics pipeline based on time-delay correlation. In order to reduce the complexity
of the transcriptional response we generated 14 gene clusters with distinct expression profiles
using the HOPACH algorithm [59]. The clusters were categorized into rapid (1–12hr), inter-
mediate (13–24hr) or delayed-responders (37–48hr) to implantation (no clusters fell into the
25–36hr category) according to the time point at which the expression profile was altered by
50% of the dynamic range (S3 Fig). In order to increase the number of data points available for
correlation analysis we first identified the median expression profile of each cluster and then
applied a polynomial interpolation algorithm to generate 100 data points. The correlation
matrix between the interpolated expression profiles was calculated using Spearman’s Ranking
Coefficient with the addition of a time-delay procedure. Interpolated expression profiles were
considered correlated with a time-delay if a shift of one expression profile by 13–24 hours (1–2
time points) improved the correlation value. The time-delay procedure identified the maxi-
mum correlation value within this time-delay window. Clusters with a highly stringent correla-
tion value of>0.9 were considered significantly correlated.
The static transcriptional networks of genes highly correlated to expression of Rho GTPases
in the CAM tumour implantation were identified using the ARACNE method [58]. A range of
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high stringency p value thresholds (p< 10−6, p< 10−7, p< 10−8) were applied in order to iden-
tify the most highly connected GTPases independent of statistical confidence.
RND3 siRNA (siRND3) knock-down
To knockdown expression of RND3 U87 cells were transiently transfected with two custom
siRNA oligos (9 pmol) supplied by Dharmacon (oligo A 5’-AUAGUAGAGCUCUCCA
AUCA-3’ or oligo B 5’-CAAACAGAUUGGAGCAGCU-3’) using Lipofectamine RNAiMAX
(Invitrogen) as described elsewhere [60]. Control, non-silencing, oligos were purchased from
Qiagen. Knock-down was confirmed to last up to 96 hours by western-blot analysis (S10 Fig).
Western blot analysis
Protein were separated by SDS-PAGE and then transferred to nitrocellulose membranes using
previously described methods [61]. Western blotting was performed using antibodies against
cleaved Caspase 3 (Cell Signalling Technology), RND3 (Millipore), MCM3 (Abcam), Lamin A/
C (Santa Cruz Biotechnology), α-tubulin (Sigma) and Flag (Sigma M2). The western blot
bands were quantified using ImageJ Software.
Microarray analysis of implanted tumours and U87 cells
RNA was extracted from U87 cells and snap frozen tumours using RNeasy columns (Qiagen,
UK). RNA purity was assessed using a NanoDrop spectrophotometer and each sample had a
260/280 ratio of 1.8–2.1. RNA was reverse transcribed and the cDNA was labelled with fluores-
cent Cy3 dye using the Agilent Low-input Quick Amp Kit (Agilent, UK). cRNA was purified
using RNeasy columns (Qiagen, UK) and hybridised overnight to Agilent Human 8x60k
Whole Genome or Agilent Chicken V1Whole Genome microarrays according to the manufac-
turer’s protocol. Microarrays were scanned using an Agilent SureScan microarray scanner and
processed using Agilent Feature Extraction software. Data was normalised using quantile
normalisation.
In order to remove probes from the analysis that could potentially hybridise to both chicken
and human cRNA we performed a separate microarray analysis. We created separate pools of
RNA from CAM and U87 cells to create chicken and human reference samples. The chicken
and human reference RNA was then hybridised to both human and chicken whole genome
microarrays. RNA extraction, generation of fluorescently labelled cRNA, microarray hybridisa-
tion and scanning protocols were identical to those used for the implanted tumour tissue. After
subtraction of the background signal, the relative contribution of the human cRNA to the total
fluorescence observed for each probe on the chicken array was calculated, and vice versa. Any
probe for which the cross-hybridisation of cRNA from the other species resulted in a fluores-
cent signal> 64 or the relative contribution to the total signal was greater than 15% was
removed. 5,272 probes were removed from the chicken dataset and 9,128 probes were removed
from the human dataset.
Genes differentially expressed during the time course of U87 implantation on the CAMwere
detected using a two-step method. First, genes with a minimum fold change of 1 in log2 scale
were selected, then noisy genes were removed using the BETR [62] algorithm with α = 0.001.
Genes differentially expressed in U87 cells in response to siRND3 treatment were detected
using the SAMmethod [63]. Genes with a false discovery rate of 5% or lower were deemed
significant.
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Development of a novel network modularisation algorithm and its
application to define the RND3 interactome
We developed a procedure derived from the work of Dittrich et al [64], which uses the prize-
collecting Steiner tree framework to identify network modules in protein-protein interaction
data. However, our novel procedure is able to integrate three independent sources of data
including known protein-protein interactions, differential gene expression and correlation
structure. This was applied to identify networks of RND3-interactors that are enriched with
co-expressed genes linked to glioma grade and therefore potentially important for tumour pro-
gression. The development of the algorithm and application to simulated data is described in
S1 Text.
Cell proliferation, migration and invasion assays
For proliferation, migration and invasion assays U87 (5x104 cells/well) cells were plated in
96-well plates. For siRNA proliferation experiments, siRND3 or siControl transfections were
performed 24h before plating. 1x105 or 5x105 T98G or 1321N1 cells respectively were plated
for proliferation and migration assays. Each cell line was infected with control GFP-Turbo or
myc-RND3 lentiviral plasmids to a MOI of 10. IncuCyte technology (Essen Bioscience) was
used to generate measurements of cell proliferation, migration and invasion over time. Growth
curves (proliferation) were built from confluence measurements acquired during round-the-
clock kinetic imaging. For invasion and migration assays cells were plated in 96-well Image-
Lock plates (Essen Bioscience). Wells were pre-coated for 6h with 50μg/ml of reduced matrigel
(BD Biosciences). For invasion assay 150μg/ml of reduced matrigel was added on each well. At
90–100% of confluence the plates were scratched with a 96-Well WoundMaker (Essen Biosci-
ence). Migration/invasion was detected by IncuCyte scanning one image per well, every two
hours for 18 hours. The time-course of cell migration/invasion was quantified using percentage
of scar recovery (cells migrated/invaded into the wound) at 2 h time intervals. Proliferation
was measured by Bromodeoxyuridine (BrdU) labelling of U87 cells using the BrdU Labelling
and Detection Kit I (Roche) according to the manufacturer’s instructions.
Apoptosis assays
To induce apoptosis, U87 cells were treated with 5μMROCK inhibitor Y-27632 and/or 50 μM
cisplatin (cis-diammineplatinum(II)dichloride) for 16 hours and apoptosis assessed by detec-
tion of cleaved caspase 3 by western blot or by staining cells with DAPI (4',6-diamidino-2-phe-
nylindole, Invitrogen) and counting the number of cells with condensed nuclei, as previously
described [60].
Immunohistochemistry
Tumour grafts grown on chicken egg CAM were excised, fixed with 4% paraformaldehyde for
5 minutes and processed for cryo-sectioning. Ten micrometre sections were placed on Super
Frost slides and immunohistochemistry was performed directly after fixation of the tissue on
the slide with 4% paraformaldehyde. For immunohistochemistry, we used the following pri-
mary antibodies: anti-human Vimentin (1:400; Santa Cruz), anti-human Ki-67 (1:200; Santa
Cruz) and anti-Desmin (1:100; clone D33 from DAKO). Corresponding fluorescent secondary
antibodies were fromMolecular Probes (1:1,000, Invitrogen). Chick blood vessels were visual-
ized by using fluorescein-coupled Sambucus nigra lectin-FITC (SNA-1 lectin, 1:100, Vector
Laboratories). Cell nuclei were visualized by DAPI (Invitrogen). Fluorescent labelling was
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viewed by confocal microscopy (Nikon). Quantification of staining was performed using Ima-
geJ software.
Paraffin-embedded formalin-fixed glioma tissue sections were deparaffinized and heated at
99°C for 20 min in 10 mM citrate buffer at pH 6.0 or incubated with proteinase K diluted in
0.05 M Tris—Cl, pH 7.5 at 37°C for 10 min. The sections were incubated with the following
primary antibodies: anti-RND3 (Abcam ab79999, 1/100). Primary antibodies were incubated
overnight at 4°C. Detection was performed using a biotinylated secondary antibody (Vector
Laboratories) amplified with Vectastain ABC Reagent (Vector). Sections were developed using
303-diaminobenzidine (DAB, DAKO), following the manufacturer’s instructions. The immu-
nohistochemical stainings were analyzed and pictures were taken with a Nikon light micro-
scope (Nikon Eclipse E600, Melville, NY, USA) using Nikon imaging software (Nikon NIS
Elements v 4.11).
Imaging of MCM3 localisation was performed on U87 cells transfected with siRND3 or
non-silencing control oligos. PFA (4%) fixed cells were stained for MCM3 (1:200, Abcam) and
fluorescent labelling was viewed using a Nikon Eclipse Ti system.
Identification and validation of RND3 binding proteins
HEK293T or U87 cells were transfected with pCMV-Flag-RhoE (RND3) or pCMV-Flag as a
control as previously described [23]. To discover putative RND3 binding proteins cell lysates
were immunoprecipitated using anti-Flag conjugated beads (Sigma). After SDS-PAGE and
staining with coomassie blue the gel was cut into 7 equal fragments and subjected to in-gel
trypsin digestion (along with matching gel slices from empty vector control) and analysed by
mass spectrometry.
Co-immunoprecipitation of Flag-RND3 with Mcm3 was performed on U87 cells. Cells
were washed with ice-cold serum-free medium and lysed on ice in buffer containing 20 mM
Tris-HCl (pH 7.4), 150 mMNaCl, 1 mM EGTA (pH 8.0), 1 mM EDTA (pH 8.0), 2.5 mM pyro-
phosphate, 1 mM β-glycerophosphate, 1% Triton X-100 containing freshly added protease,
and phosphatase inhibitor cocktail tablets (Roche). Lysates were clarified by centrifugation at
4°C, and the protein concentrations were determined by using Bio-Rad protein assay reagent
(Bio-Rad Laboratories). For immunoprecipitation analyses, aliquots of cellular lysates were
incubated with 2 μg of monoclonal anti-Flag (Sigma M2) for 1 h at 4°C. Immunocomplexes
were collected on protein G-Sepharose beads (Sigma). The beads were washed three times with
lysis buffer then boiled for 5 min in Laemmli sample buffer.
Mass spectrometry
HEK293T cells were used for mass spectrometry analysis. UltiMate 3000 HPLC series (Dionex,
Sunnyvale, CA USA) was used for peptide concentration and separation. Samples were trapped
on uPrecolumn Cartridge, Acclaim PepMap 100 C18, 5 um, 100A 300μm i.d. x 5mm (Dionex,
Sunnyvale, CA USA) and separated in Nano SeriesTM Standard Columns 75 μm i.d. x 15 cm,
packed with C18 PepMap100, 3 μm, 100Å (Dionex, Sunnyvale, CA USA). The gradient used
was from 3.2% to 44% solvent B (0.1% formic acid in acetonitrile) for 30 min. Peptides were
eluted directly (~ 300 nL min-1) via a Triversa Nanomate nanospray source (Advion Biosci-
ences, NY) into a LTQ Orbitrap Velos ETD mass spectrometer (ThermoFisher Scientific, Ger-
many). The data-dependent scanning acquisition in positive ion mode was controlled by
Xcalibur 2.7 software. The mass spectrometer alternated between a full FT-MS scan (m/z 380–
1,600) and subsequent collision-induced dissociation (CID) MS/MS scans of the 7 most abun-
dant ions. Survey scans were acquired in the Orbitrap with a resolution of 30,000 at m/z 400
and automatic gain control (AGC) 1x106. Precursor ions were isolated and subjected to CID in
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the linear ion trap with AGC 1x105. Collision activation for the experiment was performed in
the linear trap using helium gas at normalized collision energy to precursor m/z of 35% and
activation Q 0.25. The width of the precursor isolation window was 2 m/z and only multiply-
charged precursor ions were selected for MS/MS. MS/MS scans were searched against NCBI
database using Mascot algorithm in Proteome Discoverer 1.1 software (Thermo Fisher Scien-
tific). Variable modifications were deamidation (N and Q), oxidation (M) and phosphorylation
(S, T and Y). The precursor mass tolerance was 10 ppm and the MS/MS mass tolerance was
0.8Da. Two missed cleavage was allowed and were accepted as a real hit protein with at least
two high confidence peptides.
Preparation of nuclear and cytoplasmic fractions
To prepare nuclear and cytoplasmic fractions trypsinised cells (3x106) were washed in ice cold
PBS and incubated in 500μl RSB (10mM Tris pH 7.4, 5mMMgCl2, 10mM KCl) containing
0.5% v/v NP40 and protease inhibitors for 5 min on ice before being centrifuged at 500g for 5
minutes. 150μl of the supernatant (cytoplasmic fraction) was removed and 30μl of 6x protein
sample buffer added. The pelleted nuclei were resuspended in 1ml of RSB and centrifuged for 5
minutes at 500g. This was repeated and the pellet re-suspended in 150μl of protein sample
buffer. To confirm clear separation of nuclear and cytoplasmic fractions lysates were analysed
by western blot with Lamin A/C (nuclear marker) and α-tubulin (cytoplasmic marker).
Single cell imaging
Single cell imaging of RND3 localisation was performed using U87 cells transfected with
RND3-GFP (Addgene #23229) alone (with DAPI stain) or RND3-GFP and H2B-mcherry
(Addgene #21044) plasmids. Transfection involved 24h incubation with a mixture of Tran-
sIT-LT-1 transfection reagent (Mirus BIO) in a ratio of 3:1 with plasmid DNA. Confocal imag-
ing was carried out on a Zeiss LSM510 microscope using either 20x Fluar 0.8 NA or 63x
Planapochromat 1.4 NA objectives at a temperature of 37°C, 5% CO2 and humidified atmo-
sphere. Z-stack images were taken at sequential 1um depth slices. Fluorescence recovery after
photo-bleaching (FRAP) experiments involved similarly-sized regions of the cytoplasm and
nuclear compartments exposed to 20 iterations of a 488nm argon-ion laser set to 100% power.
FRAP and Z-stack live cell imaging was carried out at the Centre for Cell Imaging, IIB, Uni-
versity of Liverpool, UK.
Linking RND3 to GBM subtypes
To investigate if expression of RND3 is dependent on GBM subtype [8], genes with known sig-
natures and genetic mutations influencing the subtype were compared with RND3. The eight
genes included: NF1, PDGFRA, IDH1, EGFR, TP53, FIP1L1 (FIP1L1 can become a fusion pro-
tein with PDGFRA), PTEN and CDKN2A. Normalized gene expression, scaled CNV and
somatic mutation data free from batch effects was downloaded from the MD Anderson Bioin-
formatics Cancer Genome Atlas MBatch resource (bioinformatics.mdanderson.org/tcgam-
batch). A regression analysis was performed using either univariate regression or the ensemble
classification and regression algorithm Random Forest (RF), where RND3 was used as the
dependent variable and the 8 gene CNV and expression data as the predictor variables. The
most influential predictor variables and the % variability of RND3 expression explained by the
RF models are reported.
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Survival analysis
The effects of alterations in expression and copy number variation of Rho GTPases on glioblas-
toma patient survival was assessed using the REMBRANDT [29] and TCGA databases. The
online tools available on the REMBRANDT website (www.caintegrator.nci.nih.gov/
rembrandt) were used to generate Kaplan-Maier survival curves and log rank p values. Simi-
larly, the TCGA data was analysed by first calculating ranks for each patient according to the
expression or standardised CNV of RND3, and then finding the optimum partitioning of
patients that maximises the significance of the Cox regression model. This was then used to
generate Kaplan-Maier survival curves and log rank p values.
Accession numbers
The following datasets are deposited within Gene Expression Omnibus: Implantation of U87
cells on the chicken CAM (GSE43674), RND3 silencing in U87 cells (GSE43812).
Supporting Information
S1 Dataset. Gene Ontology analysis of the genes found within network modules M1–M4.
Gene lists have been split into those up-regulated or down-regulated in grade 4 glioma com-
pared to grade 2 glioma. Significantly enriched Gene Ontology terms were selected using a 10%
False Discovery Rate cut-off.
(XLSX)
S2 Dataset. Rho GTPase gene connectivity in networks derived from the Cancer Genome
Atlas glioma grade II and IV datasets. Rho GTPase connectivity was assessed in multiple
ARACNE networks at different significance levels for gene-gene connections (p-values< 1e-5
or 1e-6). The same threshold used for the original data was used for defining Rho GTPases with
strong grade specific connectivity (the proportion of grade II connections / proportion grade
IV connections> 0.4 or< -0.4).
(XLSX)
S3 Dataset. Gene Ontology analysis of genes connected to Rho GTPases in the grade II and
grade IV gene expression networks. The Gene Ontology analysis of the network neighbour-
hood of grade II specific Rho GTPases in grade II networks and the network neighbourhood of
grade IV specific Rho GTPases in the grade IV networks are shown in separate worksheets. No
filtering has been applied, all mapped Gene Ontology terms and the relevant genes are
included.
(XLSX)
S4 Dataset. Gene lists and Gene Ontology terms mapped to gene clusters in the high level
map of transcriptional changes in the chicken CAM glioblastoma implantation model.
Gene Ontology analysis has been performed on genes regulated at each level of the transcrip-
tional map (1–13hrs up, 13–24hrs down, 13–24hrs up, 37–48hrs down, 37–48hrs up-regulated-
). All mapped Gene Ontology terms are included.
(XLSX)
S5 Dataset. Gene Ontology analysis of genes up-regulated in U87 siRND3 cells compared
to U87 siControl cells. All mapped Gene Ontology terms are included.
(XLSX)
S1 Fig. A comparison of differentially expressed genes between grade II and grade IV gli-
oma in two independent datasets. Enrichment score (ES) plots generated by comparing
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differentially expressed genes between grade II and grade IV glioma in GSE4290 and
GSE52009 datasets using the Gene Set Enrichment Analysis software. False discovery rate
<0.001% for both comparisons.
(TIF)
S2 Fig. Rho GTPase gene expression in different glioma grades. The expression of Rho
GTPases in the Sun et al dataset is represented as a colour heatmap. Gene expression is stan-
dardised by row for visualisation. Mean linear fold change values are indicated for each glioma
grade comparison. Statistical significance is determined by t-test followed by Benjamini-
Hochberg FDR correction.
(TIF)
S3 Fig. Correlation network of gene expression changes in U87 derived tumours implanted
on the chicken egg CAM. 14 distinct gene clusters are categorised as early (1–12hrs; top row),
intermediate (13–24hrs; middle row) or delayed responders (37–48hrs; bottom row) according
to the time point at which the gene expression is altered by 50% of the dynamic range of the
cluster. The time window (pink bar) and exact position in the interpolated time series (dotted
line within pink bar) at which the cluster has altered by 50% of the clusters dynamic range is
shown in respect to the medoid expression profile of each cluster (black line) and the interpo-
lated expression profile (red line). Significant time-delay correlations between expression pro-
files are shown as dotted lines between clusters. Genes within each group of clusters (early,
intermediate, and delayed) were determined to be up or down-regulated according to the
expression trend of the cluster. A representative selection of Gene Ontology terms enriched
within up (red) and down-regulated (green) genes at each level are coloured accordingly
(false discovery rate< 10%). ns: non-significant. Individual genes within each cluster are col-
oured according to function: Rho GTPase (blue), secreted factor (green) and known oncogene
(red).
(TIF)
S4 Fig. The network neighbourhood of Rho GTPases in the CAM implantation model
reveal RND3 is a hub gene. A. The gene neighbourhood of Rho GTPases RHOBTB1,
RHOBTB2, RND3 and RHOC in the CAM network (mutual information p value< 10−6). B.
The size of the gene neighbourhood of RND3 and RHOC at a range of high statistical thresh-
olds.
(TIF)
S5 Fig. Functional analysis of genes differentially expressed in U87 cells following RND3
siRNA treatment.Heatmap representing expression profiles of differentially expressed genes
between U87 siControl (n = 3) and U87 siRND3 (n = 3) cells. The number of genes matched to
Gene Ontology terms within up and down-regulated genes are shown. Terms in bold are sig-
nificantly enriched (false discovery rate< 10%). ns = non-significant.
(TIF)
S6 Fig. Expression of key genes controlling angiogenesis, cell proliferation and extracellular
matrix remodelling is reduced in U87 siRND3 cells.Heatmap representing expression pro-
files of a selection of differentially expressed genes related to extracellular processes.
(TIF)
S7 Fig. Ectopic expression of RND3 in low expressing RND3 cells induces aggressive cell
behaviors. A.Western blot analyses with RND3 and tubulin antibodies on U87, T98G and
1321N1 cells. B.Western blot analyses with RND3 and tubulin antibodies on myc-RND3
expressing T98G and 1321N1 cells. C. Ectopic expression of RND3-GFP or myc-RND3 in
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T98G and 1321N1 cells. RND3-GFP or myc-RND3 are represented in green and F-actin/DAPI
stainings in red and blue respectively. Scale bars, 10 μm.
(TIF)
S8 Fig. In vivo staining of Vimentin and Desmin after implantation of U87 siRND3 on the
CAM. Biomicroscopic pictures from tumors grown on the CAM. A-D. Representative immu-
nohistochemistry staining of vimentin (A, B) or desmin (C, D). Tumors derived from U87
siControl (A, C) or U87 siRND3 (B, D) cells. Magnifications: (A, B) x10; scale bar 200μm, (C,
D) x20; scale bar 100μm.
(TIF)
S9 Fig. RND3 is predictive of survival in TCGA datasets. Kaplan-Meier survival curves of gli-
oma patients partitioned by lower or higher RND3 expression and CNV in TCGA datasets.
(A) The higher RND3 expression (n = 70) group has significantly lower survival rates than the
low RND3 expression group (n = 165), p = 0.012, HR = 1.1–2.2. (B) The higher RND3 CNV
(n = 317) group has significantly lower survival than the low RND3 CNV group (n = 119),
p = 0.011, HR = 1.1–1.7.
(TIF)
S10 Fig. RND3 knockdown is maintained for 96 hours in U87 cells. RND3 expression deter-
mined by western blot in U87 cells 24, 48, 72 and 96 hours after transfection with RND3
siRNA.
(TIF)
S11 Fig. Western blot showing expression of RND3 within nuclear fraction of U87 cells. A.
Detection of RND3 in whole cell lysates, nuclear fraction and cytoplasmic fraction of U87 cells
determined by western blot. Lamin A/C and α-tubulin are included as exclusively nuclear/cyto-
plasmic controls respectively. B.Quantification of the western blot analysis by densitometry.
(TIF)
S12 Fig. RND3 is expressed within the nucleus. A-B.Fluorescence recovery after photo-
bleaching (FRAP) time-course for U87 cells expressing RND3-GFP. Cells were bleached after
indicated time point using 20 iterations of 488nm laser set to 100%. Same-sized regions were
bleached in the (A) entire nucleus (n = 14 cells) and (B) fraction of the cytoplasm (n = 6 cells).
Fluorescence recovery was monitored and data plotted normalised to pre-bleach fluorescence
intensity ± standard deviation. C. Image series showing representative U87 cell expressing
H2B-mcherry (red) and RND3-GFP (green), imaged in sequential 1um depth ‘slices’ through
the cell.
(TIF)
S13 Fig. RND3 expression in Glioma subtypes. A. RND3 gene expression in patients with
glioblastoma subtypes defined by Verhaak et al, 2010. Data consists of glioblastoma patients
from the Cancer Genome Atlas database. B. Change in expression of genes characteristic of the
mesenchymal subtype in U87 cells after RND3 silencing. C. Significance and percentage of var-
iance in RND3 expression explained by univariate regression analysis using CNV or mRNA
levels of frequently mutated genes in GBM. The top 5 models are shown.D-E. Variable weights
from a Random forest correlation model linking (D) copy number variation [CNV] and
somatic mutations [SNP:ID] or (E) copy number variation, gene expression [mRNA] and
somatic mutations from the TCGA database to RND3 expression. Percentage of variance in
RND3 expression explained: D– 13.97%, E– 21.04%. Plus or minus symbols indicate sign of
the Spearman correlation value between RND3 and CNV/mRNA expression.
(TIF)
Glioma Gene Regulatory Networks and the Role of RND3 in Cancer
PLOS Genetics | DOI:10.1371/journal.pgen.1005325 July 1, 2015 25 / 29
S1 Text. A novel modularization approach to integrating multiple functional genomics
datasets. This document describes the background, methodology and performance of the
novel multi-level data integration approach used in this study to generate the networks in
Fig 6A.
(DOCX)
S1 Table. Functional enrichment analysis reveals common terms linked to genes correlated
with RND3 expression and/or modulated by RND3 silencing. Significant enrichment indi-
cated by bold text (false discovery rate< 10%).
(TIF)
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